Indaptus Therapeutics, Inc.

The momentum for this stock is not very good. Indaptus Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Indaptus Therapeutics, Inc..
Log in to see more information.
INDP Fundamental Data by TradingView

News

Indaptus Therapeutics files to sell 1.64M shares of common stock for holders
Indaptus Therapeutics files to sell 1.64M shares of common stock for holders

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Indaptus Therapeutics to initiate dosing of patients at higher Decoy20 dose
Indaptus Therapeutics to initiate dosing of patients at higher Decoy20 dose

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

Globe Newswire NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ( Indaptus or the Company ), a clinical stage biotechnology company dedicated to pioneering innovative...\n more…

Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the...\n more…

Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Decoy20 Clinical Developments
Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Decoy20 Clinical Developments

TipRanks Financial Blog Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Indaptus Therapeutics (INDP - Research Report). The associated price targ...\n more…

INDP Stock Earnings: Indaptus Therapeutics Beats EPS for Q2 2024
INDP Stock Earnings: Indaptus Therapeutics Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nINDP stock results show that Indaptus Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…